- Companies
- MeMed
MeMed Funding, Investors & Competitors
MeMed has raised $163M across 2 funding rounds, most recently a $93M Series E in January 2022.
Last MeMed funding round
$93M
Series E · Jan 2022
Cumulative funding MeMed raised
$163M
across 2 funding rounds
Key investors in MeMed
Social Capital
Horizons Ventures
Western Technology Investment
Phoenix Financial
Clal Insurance
Caesarea Medical Electronics
OurCrowd
Foxconn
About MeMed
MeMed is a Haifa-headquartered diagnostics company founded in 2009 developing ImmunoDx tests distinguishing bacterial from viral infections. The platform analyzes immune biomarkers to guide antibiotic prescriptions, addressing global misuse in a market exceeding $25 billion. Products serve hospitals in Israel, Europe, and the US.
Founded
2009
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales, Subscription
MeMed Funding History
MeMed has raised a total of $163M across 2 funding rounds.
MeMed's first fundraising round was a $70M Series C in September 2018. The most recent completed round was a $93M Series E in January 2022.
MeMed funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Jan 2022 | Series E | Horizons Ventures (lead); Caesarea Medical Electronics; Touchwood Capital; Poalim Equity; La Maison Partners; Social Capital; Clal Insurance; Western Technology Investment; Union Tech Ventures; Phoenix Financial; Shavit Capital | $93M | MeMed, an Israeli healthtech company founded in 2009 by Eran Eden and Kfir Oved, develops host response technologies to diagnose diseases by analyzing the immune system's signals, distinguishing between bacterial and viral infections. Its key product, MeMed BV test, received US FDA clearance shortly before the funding announcement to aid in point-of-need diagnosis via the MeMed Key platform. The company also worked on tests for predicting COVID-19 deterioration risk and has partnerships including with the US Department of Defense and EU Commission. On January 10, 2022, MeMed raised $93 million in a private financing round (described variably as Series C or Series E across sources), led by Horizons Ventures, with participation from Shavit Capital, Social Capital, La Maison Partners, Touchwood Capital, Caesarea Medical Electronics (or Holdings), Clal Insurance, Phoenix Insurance (or Financial), Poalim Equity, and Western Technology Investment, among others. This brought total funding to over $200 million across multiple rounds since 2013. Funds were allocated to scale manufacturing, accelerate US-focused commercialization, expand sales teams (including over 20 in Boston), and grow the host immune response product portfolio. Headquartered in Haifa with about 100 employees across Israel, Europe, and the US, MeMed positions itself as a leader in reducing antibiotic overuse and improving infection triage amid antimicrobial resistance and COVID-19 challenges. Investors highlighted its potential to transform diagnostics. Management remains Israel-based with no plans for a US CEO. |
| Sep 2018 | Series C | Caesarea Medical Electronics; Foxconn; Li Ka-shing; Ping An Global Voyager; Social Capital; Horizons Ventures; Clal Insurance; OurCrowd; Western Technology Investment; Phoenix Financial | $70M | MeMed is an Israeli medical diagnostics company based in Haifa that develops host immune response technologies to decode the body's immune response to infection. The company's primary product, MeMed BV, is a blood test that distinguishes between bacterial and viral infections by measuring immune system biomarkers and using machine learning algorithms to recognize patterns linked to different types of infection. The test was CE-marked in Europe and has demonstrated accuracy across patients with respiratory tract infections, urinary tract infections, and fever of unknown origin. In September 2018, MeMed completed a $70 million Series C funding round led by Ping An Global Voyager Fund, with participation from Foxconn, Caesarea Medical Holdings, Clal Insurance, Phoenix Insurance, OurCrowd, Social Capital, Western Technology Investment, Horizons Ventures, and others. This brought the company's total equity raised to $100 million, plus over $25 million in grants from governmental entities including the European Commission and U.S. Department of Defense. The proceeds were allocated toward manufacturing scale-up, completing development of the MeMed Key point-of-care platform that can run the test in minutes, expanding the product pipeline with machine learning-based tests for other clinical applications, and expanding market adoption in clinical settings. The company aimed to position the Key platform to bring central laboratory precision to point-of-care diagnostics, enabling measurement of multiple protein signatures and biomarkers that previously required centralized lab infrastructure. |
Who has invested in MeMed?
15 investors have backed MeMed across its funding rounds, including Social Capital, Horizons Ventures, Western Technology Investment, Phoenix Financial, Clal Insurance and Caesarea Medical Electronics.
Lead investors include Horizons Ventures.
MeMed Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Participant | Sep 2018 | ||
| 2 | Participant | Sep 2018 | ||
| 2 | Lead | Sep 2018 | ||
| 2 | Participant | Sep 2018 | ||
| 2 | Participant | Sep 2018 | ||
| 2 | Participant | Sep 2018 | ||
| 1 | Participant | Sep 2018 | ||
| 1 | Participant | Sep 2018 | ||
| 1 | Participant | Jan 2022 | ||
| 1 | Participant | Sep 2018 | ||
| 1 | Participant | Jan 2022 | ||
| 1 | Participant | Jan 2022 | ||
| 1 | Participant | Sep 2018 | ||
This data is available for Pro users. Sign up to see all 15 MeMed investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialMeMed Competitors
MeMed competitors include listed companies like IDEXX Laboratories, IQVIA, GE HealthCare and ICON plc, and private ones like BrightInsight and Benchling.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $4.3B | $1.5B | $40B | 8.9x | ||
| Private | - | - | $750M | - | ||
| Publicly listed | $16B | $3.4B | $44B | 3.4x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $8.3B | $816M | $13B | 1.9x | ||
| Private | $210M | - | $6.1B | 29.0x |
MeMed Public Comps
MeMed is still privately-owned, but its public comps include Roche, Natera, IQVIA, Veeva, IDEXX Laboratories, Roper Technologies, Illumina, GE HealthCare, Guardant Health and ICON plc.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $2.3B | ($266M) | 22.5x | 19.0x | (195.0x) | (261.5x) | |||
| $16B | $3.4B | 3.6x | 3.4x | 17.2x | 14.8x | |||
| $3.2B | $965M | 11.1x | 10.2x | 36.9x | 22.4x | |||
| $4.3B | $1.5B | 9.5x | 8.9x | 27.1x | 24.9x | |||
| $7.9B | $3.2B | 6.1x | 5.7x | 15.2x | 14.6x | |||
| $4.3B | $1.4B | 8.8x | 8.4x | 27.1x | 30.0x | |||
| $21B | $3.7B | 1.8x | 1.8x | 10.1x | 10.0x | |||
This data is available for Pro users. Sign up to see all MeMed competitors and their valuation data. Start Free Trial | ||||||||
Common questions about MeMed
| When was MeMed founded? | MeMed was founded in 2009. |
| Where is MeMed headquartered? | MeMed is headquartered in Tirat Carmel, Israel. |
| Is MeMed publicly listed? | No, MeMed is a private, VC-backed company. |
| How much funding has MeMed raised? | MeMed has raised $163M across 2 funding rounds. |
| What was MeMed's last funding round? | MeMed's last funding round was a $93M Series E in January 2022, led by Horizons Ventures. |
| Who are MeMed's investors? | MeMed's investors include Caesarea Medical Electronics, Social Capital, Horizons Ventures, Clal Insurance, Western Technology Investment, Phoenix Financial, Foxconn, Li Ka-shing, Touchwood Capital, Ping An Global Voyager and 5 others. |
| Which companies are comparable to MeMed? | Companies comparable to MeMed include IDEXX Laboratories, BrightInsight, IQVIA, GE HealthCare, ICON plc and Benchling. |
See companies similar to MeMed
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




